Figure 2.

 Kaplan-Meier survival curves showing the effects of cell cycle proteins and clinical stages on overall survival of patients with non-small cell lung cancer. (A) Negative expression of cyclin D1 was associated with shorter patient survival; (B) positive expression of p16 correlated with improved outcome; (C) positive expression of retinoblastoma protein 2 (pRb2)/p130 was associated with improved outcome; (D) patients with negative expression of pRb2/p130, cyclin D1, and p16 (group C) had a significant shorter overall survival (see table 5 for the definition of the patient groups).